LRP1 and Alzheimer disease: Targeting restoration of LRP1 or GLUT1 expression may lead to increased LRP1-mediated Aβ clearance, representing a novel strategy for AD therapy. Indeed, additional efflux transporters such as P-glycoprotein may also be targets to promote Aβ clearance [184].